| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5648320 | Journal of the American Academy of Dermatology | 2017 | 13 Pages |
Abstract
Guselkumab demonstrated superior efficacy compared with adalimumab and was well tolerated in patients with psoriasis through 1Â year.
Keywords
T helperscalp psoriasisPASI 100PASI 90PASI 75NAPSIDLQIAdalimumabHRQOLPGAISREfficacyInvestigator Global AssessmentPhysician global assessmentSafetyIgAinterleukinPASItumor necrosis factor-alphaNail Psoriasis Severity IndexDermatology Life Quality Indexadverse eventTNF-αpsoriasis area and severity indexinjection site reactionPsoriasisnail psoriasisHealth-related quality of life
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Andrew MD, MBA, Kim A. MD, PhD, Christopher E.M. MD, Bruce MD, PhD, Yasmine MD, PhD, Yaung-Kaung PhD, Shu PhD, Alexa B. MPH, MD,